Printer Friendly

A Novel Homozygous CYP19A1 Gene Mutation: Aromatase Deficiency Mimicking Congenital Adrenal Hyperplasia in an Infant without Obvious Maternal Virilisation.

What is already known on this topic?

In aromatase deficiency, the accumulated androgens may cause signs of maternal virilisation during pregnancy. Large multiple cysts have been described in aromatase deficient girls during infancy and childhood. In previous reports of aromatase deficiency, cases were term neonates of average weight for gestational age.

What this study adds?

In this report, we describe a case of aromatase deficiency showing disorder of external genital development in a preterm infant born at age 23 weeks. A report a novel large deletion in the CYP19A1 gene was shown. Maternal virilisation was not a marked finding in our case, except for a mild deep voice. The absence of virilisation in our patient's mother could likely be due to the premature delivery of the patient.


Aromatase (cP450arom) catalyses the conversion of androgens to estrogens. The biological importance of aromatase is related not only to its role in estrogen biosynthesis, but also to its potential influence on the balance of the androgen-estrogen ratio in different tissues. In humans, cP450arom is encoded by a single gene (CYP19A1), that is located on chromosome 15q21.1. The protein-coding sequence is contained within nine exons (E2-E10), spanning approximately 35 kb (1,2,3). The CP450arom enzyme is mainly located in the endoplasmic reticulum of estrogen-producing cells in the ovary, placenta, testis, brain, adipose tissue, liver, muscle and hair follicles (4,5).

Aromatase deficiency is a rare, autosomal recessive disorder in which affected patients do not have normal estrogen synthesis (1). During pregnancy, dehydroepiandrosterone sulphate (DHEAS) and 16OH-DHEAS, arising from the fetal adrenal gland and liver, respectively, become important sources for the synthesis of placental estrogens (4,5,6). Fetuses lacking aromatase activity are not able to convert DHEAS to estrogens in the placenta. DHEAS is therefore converted to testosterone, resulting in the virilization of both fetus and mother. Since the first description of aromatase deficiency by Shozu et al (7) in 1991, around 40 cases have been reported (1,3,4,5,7,8,9,10,11,12,13,14,15,16,17,18,1 9,20).

In aromatase deficiency, the accumulated androgens may cause signs of maternal virilisation (acne, deep voice, clitoral enlargement) during pregnancy. After delivery these symptoms usually disappear gradually. In the postpartum period, some clinical and laboratory findings of androgen excess regress and androgen levels return to normal levels. In most female infants exposed in utero to excessive androgen levels, ambiguous genitalia have been reported. Delayed skeletal maturation has been described and most affected girls have multiple ovarian cysts and failure of breast development at puberty (3,5).

Herein, we report a 46, XX patient born with virilised external genitalia. A novel homozygous mutation in the CYP19A1 gene, causing aromatase deficiency, was detected.

Case Report

A 30-days old infant with a male-dominant genital appearance was referred to pediatric endocrinology because of a uterus, detected on ultrasonography. The infant was born at 23 weeks of gestation by C-section because of preeclampsia and premature membrane rupture. The parents were consanginenous. Birth weight was 680 gr. The infant was intubated, given surfactant treatment and required mechanical ventilation support. Bilateral cryptorchidism and hypospadias were thought to be associated with the severe prematurity. Since gender assessment at birth was made as male, the baby received a male name and identity card. He was the first baby of a 25-year old healthy mother and a 27-year old healthy father who were first cousins. The mother had had two abortions in the past, so she was treated with progesterone for one month between the 16th and 20th gestational weeks and also with salicylic acid throughout the pregnancy. There was no evidence of virilisation, such as acne, hirsutism, deep voice or clitoral enlargement in the maternal history. Physical examination of the infant revealed complete labioscrotal fusion and a single urogenital meatus, consistent with Prader stage-3. Gonads were not palpable, a chorda was present and the phallus was measured as 2x1 cm on the dorsal and 1.6x1 cm on the ventral side. At the time of the investigation the patient was still being followed in the neonatal intensive care unit and having mechanical respiratory support. On postnatal day 30, the patient's hormone levels were as follows: 17-hydroxy progesterone (17OHP): 41 ng/mL [normal limits (NL) <35.5 ng/mL], DHEA sulphate (DHEASO4): 1500 [micro]g/dL (NL 123-882 [micro]g/dL), testosterone: 2.94 ng/mL (NL 0.05-0.16 ng/mL), FSH: 1.3 IU/L (NL 0.3-2.6 IU/L), LH: 0.48 IU/L (NL 0.1-8.5 IU/L), estradiol <10 pg/mL (NL <15 pg/mL), progesterone: 4.7 ng/mL (NL 0.18-6.4 ng/mL). Karyotype was 46, XX. A standard dose adrenocorticotropic hormone (ACTH) test (30 [micro]g/kg/dose) revealed an inadequate stimulated cortisol and high 17OHP levels, suggesting simple virilising congenital adrenal hyperplasia (CAH) likely due to 21-hydroxylase deficiency (Table 1). Additionally there were several other problems, such as septicemia, surfactant deficiency and respiratory distress. The patient was on mechanical ventilation due to severe prematurity at this time. Although the classical findings of adrenal insufficiency were not present, the decision was taken to administer hydrocortisone[R] replacement since cortisol deficiency could not be excluded. Hydrocortisone[R] was commenced at a dose of 10 mg/[m.sup.2]/day, three times a day. The name and identity card of the baby were changed to female with the agreement of the parents and the decision of multidisciplinary gender assessment committee.

Over the next two years, androgen levels were quite low, despite hydrocortisone doses as low as 6-7 mg/[m.sup.2]/day, and no mutation in CYP21A2 gene was detected. This unusual clinical condition and lack of a mutation in CYP21A2 gene led to doubt concerning the security of the diagnosis of 21-hydroxylase deficiency. At the age of two years and six months the standard dose ACTH test was repeated, after suspension of hydrocortisone treatment for 48 hours. The results of this test showed the cortisol and androgen levels were normal (Table 1). When maternal history was re-evaluated, the mother remembered that she had a mild deep voice during pregnancy. The patient was re-evaluated in terms of 46, XX disorders of sex development (DSD), especially with the suspicion of aromatase deficiency (Table 2). Finally, aromatase deficiency was confirmed by genetic analysis (Figure 1).

At the last clinical visit, the patient was 4.3 years old, height was 95.5 cm (-2.3 SD), weight 14.5 kg (-1.27 SD) and breast development was Tanner stage-1. Further examinations were performed for disorders which could be associated with aromatase deficiency (Table 2).

Informed consent was obtained from the parents of the patient for publication of this case.

Genetic Analysis

An Ethylenediaminetetraacetic acid blood sample was taken for CYP19A1 gene sequence analysis. At the PCR step, as the very large region including exon 6 could not be amplified, a long PCR and sequence analysis was planned to detect exact breakpoints. Sequence analysis with a Next Generation Sequencing Method (Illumina-MISEQ, San Diego, CA, USA) was done and a 3212 bp deletion within chromosome 15:51.511.985-51.508.774 was detected (NM_000103.3:c.629-1453_744-486del). This large deletion was evaluated as a likely "pathogenic" variant due to ACMG criteria.

The CYP19A1 gene contains 10 exons and exon 6 was largely deleted with some parts of introns of both sites and two canonical splice sites. This was a null variant. The allele was not found in gnomAD exomes. This is a conserved region in different species. This was a novel variant.


In this report, we describe a case of aromatase deficiency in a 23-week preterm infant with a disorder of external genital development. We report a novel large deletion in the CYP19A1 gene (Figure 1). To date, more than 33 different mutations in the CYP19A1 gene have been reported in patients with aromatase deficiency. These mutations include mis-sense, splice site, non-sense, insertions and small deletions and one large intragenic deletion (1,3,4,5, 8,9,10,11,12,13,14,15,16,17,18,19,20,21,22). The majority of the mutations reported are located in exons 9 and 10, which encode the substrate-binding site and haem-binding domains, respectively (12). Our patient had a large deletion in exon 6. Although we did not make a functional study, this variant is a null variant and classified as a likely pathogenic variant due to ACMG criteria. The fact that we were not able to conduct a functional study related to the mutation we identified was the limiting factor of our study.

Aromatase deficiency causes virilisation (acne, deep voice, clitorial enlargement) in the mother because placental androgens cannot be converted to estrogens, resulting in excessive androgen levels and virilisation of the mother during pregnancy (16). While it is an important clue, maternal virilisation is not a rule. In the study of Marino et al (3), three of six cases had a history of gestational virilisation. Maternal virilisation was not a marked finding in our case, except for a mild deep voice. Why some mothers do not have signs of virilisation can be explained by either a lower fetal adrenal androgen secretion or adequate placental estrogen production (16). Grumbach and Auchus (23) reported that a placental aromatase activity as low as 1% of normal is enough to prevent maternal virilisation. Furthermore, substantial placental estrogens are produced, especially in the 3rd trimester of gestation (16). The absence of virilisation in our patient's mother could likely be due to premature delivery or to the presence of partial aromatase activity.

In most female cases of aromatase deficiency, disorders of external genitalia with various degrees of masculinization have been reported. Gonads were non-palpable and internal genitalia differentiation was normal female in these cases (1,3,4,5). For this reason, these patients can be diagnosed as CAH, which is the most common cause of virilisation in a female fetus (1). Similarly, our patient was considered to have CAH because of physical findings and also because of quite high androgen levels. In addition the severe prematurity and the lack of data about normal androgen levels in such neonates led to initial diagnostic confusion in our patient. Low androgen levels, despite low hydrocortisone doses on the follow-up, are very unusual in classical CAH patients. This important observation, together with the lack of mutation in CYP21A2, encouraged us to reconsider a diagnosis of 21-hydroxylase deficiency.

A clinical phenotype, including changes in the hypothalamic-pituitary-gonadal axis, ovarian cyst development, skeletal maturation and growth, as well as changes in insulin sensitivity and lipid profile, has been reported in aromatase deficiency (5). Marino et al (3) investigated the hypothalamic-pituitary-gonadal axis and described high levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in the neonatal period. A two-month old girl, reported by Mullis et al (17), had elevated FSH levels (baseline and GnRH-stimulated) but normal LH levels (baseline and GnRH-stimulated). Contrary to these findings, our patient had normal gonadotropin levels on postnatal day 60 (Table 2). LH and FSH levels were elevated at the ages of 26 and 52 months (Table 2). In previous reports of aromatase deficiency, cases were term neonates with average weights for gestational age (5,7,17,18). Our patient was born at the 23rd week of gestation, thus gonadotropin levels in early infancy would probably not be helpful in the diagnosis. In premature infants without aromatase deficiency, gonadotrophin levels are very high after birth, but a sharp decrease in FSH levels is seen around term age. Also, in term neonate without aromatase deficiency, gonadotrophin levels are low at birth and increase progressively afterwards (24,25). Since we measured gonadotropin levels at a near term-equivalent age, it might have been coincidental with the time of rapid decrease.

Large multiple cysts have been described in aromatase deficient girls during infancy and childhood due to chronic stimulation by gonadotropins that cannot be suppressed because of estrogen deficiency (3,5,17,18). Marino et al (3) reported a case series of five patients. Four of them, aged 18, 7, 12 and 10 years, had increased ovarian size with large cysts. They were at a pubertal stage except for the 7-year old. Only one, a 3-year old girl, had normal ovaries. There are some patients who do not have large cysts and may even have hypoplastic ovaries. To date, seven patients with hypoplastic ovaries have been reported (4,12,16,19,20). Thus, there is no consistent ovarian phenotype in patients with aromatase deficiency since some were reported to have large and polycystic ovaries, while others had normal ovarian morphology (16). Despite quite elevated levels of FSH, we did not observe any ovarian cysts in periodic ultrasonographic screening of our patient and she continues to show normal ovarian morphology.

Little is known about the bone phenotype of girls with aromatase deficiency (26). It is accepted that estrogens are important in preserving adequate bone mineral density (BMD) (5). However, data on the role of estrogens on bone mineralization during childhood are scarce. Janner et al (26) found decreased BMD in a 3.5-year old patient, while Belgorosky et al (18) reported normal BMD in a 6-year old patient. It may be true that some expression of cP450arom protein might be enough to maintain a normal mineral bone density. On the other hand, men with aromatase deficiency show a distinct bone phenotype characterized by osteopenia (27). We performed a BMD measurement in our patient at the age of four years, revealing osteopenia (-1.4 SDS) when re-calculated for the patient's height age.

The usefulness of estrogen treatment during infancy and childhood in affected female patients is not clear. Mullis et al (17) reported that low doses of estradiol in a 3-year-old affected girl resulted in normalization of serum gonadotropins, regression of enlarged ovaries and improvement in BMD. Janner et al (26) showed the positive impact of oral 17-[beta] estradiol treatment on longitudinal growth, bone age maturation, regulation of pituitary gonadotropin feedback, improving multicystic ovaries and bone density in the long-term follow-up of a girl with a compound heterozygote mutation in CYP19A1 gene. So far, our patient has not been started on estrogen treatment, since her ovaries are still normal and existing data on estrogen treatment for these patients are inadequate.

In conclusion, a novel mutation in CYP19A1 gene explains the virilisation of our patient. Aromatase deficiency could easily be confused with CAH, especially in a preterm infant. In a case of 46, XX DSD, aromatase deficiency can present without a history of maternal virilisation or in the absence of large and multycystic ovaries. The absence of virilisation in our patient's mother could likely be due to premature delivery of the patient or presence of partial aromatase activity. It is not clear if premature delivery and aromatase deficiency are related or are coincidental in our patient. The effect of inadequate androgen-estrogen conversion in placenta on the continuation of the gestational process in aromatase deficiency is not clear. In our opinion further investigation of this relationship and possible mechanisms are warranted.

This case report emphasizes the importance of considering aromatase deficiency as a very rare cause of 46, XX DSD and the need to perform genetic analyses in patients, especially in the absence of a definite diagnosis. Further published cases will enhance our knowledge of the phenotypic spectrum of aromatase deficiency.


Informed Consent: Informed consent was obtained from the parents of the patient for publication of this case.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: Fatma Dursun, Design: Fatma Dursun, Data Collection or Processing: Fatma Dursun, Serdar Ceylaner, Analysis or Interpretation: Fatma Dursun, Serdar Ceylaner, Literature Search: Fatma Dursun, Writing: Fatma Dursun, Serdar Ceylaner.

Financial Disclosure: The authors declare that this study received no financial support.


(1.) Saraco N, Nesi-Franca S, Sainz R, Marino R, Marques-Pereira R, La Pastina J, Perez Garrido N, Sandrini R, Rivarola MA, de Lacerda L, Belgorosky A. An Intron 9 CYP19 Gene Variant (IVS9+5G>A), present in an aromatase-deficient girl, affects normal splicing and is also present in normal human steroidegenic tissues. Horm Res Paediatr 2015;84:275-282.

(2.) Harada N, Yamada K, Saito K, Kibe N, Dohmaet S, Takagi Y. Structural characterization of the human estrogen synthesis (aromatase) gene. Biochem Biophys Res Commun 1990;166:365-372.

(3.) Marino R, Perez Garrido N, Costanzo M, Guercio M, Juanes M, Rocco C, Ramirez P, Warman DM, Ciaccio M, Pena G, Feyling JG, Miras M, Rivarola MA, Belgorosky A, Saraco N. Five new cases of 46,XX aromatase deficiency: clinical follow-up from birth to puberty, a novel mutation, and a founder effect. J Clin Endocrinol Metab 2015;100:301-307.

(4.) Akcurin S, Turkkahraman D, Kim WY, Durmaz E, Shin JG, Lee SJ. A novel null mutation in P450 aromatase gene (CYP19A1) associated with development of hypoplastic ovaries in humans. J Clin Res Pediatr Endocrinol 2016;8:205-210.

(5.) Belgorosky A, Guercio G, Pepe C, Saraco N, Rivarola MA. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm Res 2009;72:321-330.

(6.) Jones ME, Boon WC, Mcinnes K, Maffei L, Carani C, Simpson ER. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab 2007;3:414-421.

(7.) Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991;72:560-566.

(8.) Hauri-Hohl A, Meyer-Boni M, Lang-Muritano M, Hauri Hohl M, Schoenle EJ, Biason-Lauber A. Aromatase deficiency owing to a functional variant in the placental promoter and a novel missense mutation in the CYP19A1 gene. Clin Endocrinol (Oxf) 2011;75:39-43.

(9.) Verma N, Jain V, Birla S, Jain R, Sharma A. Growth and hormonal profile from birth to adolescence of a girl with aromatase deficiency. J Pediatr Endocrinol Metab 2012;25:1185-1190.

(10.) Ludwikowski B, Heger S, Datz N, Richter-Unruh A, Gonzalez R. Aromatase deficiency: rare cause of virilization. Eur J Pediatr Surg 2013;23:418-422.

(11.) Baykan EK, Erdogan M, Ozen S, Darcan S, Saygili LF. Aromatase deficiency, a rare syndrome: case report. J Clin Res Pediatr Endocrinol 2013;5:129-132.

(12.) Gagliardi L, Scott HS, Feng J, Torpy DJ. A case of aromatase deficiency due to a novel CYP19A1 mutation. BMC Endocr Disord 2014;14:16.

(13.) Bouchoucha N, Samara-Boustani D, Pandey AV, Bony-Trifunovic H, Hofer G, Aigrain Y, Polak M, Fluck CE. Characterization of a novel CYP19A1(aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies. Mol Cell Endocrinol 2014;390:8-17.

(14.) Zhu WJ, Cheng T, Zhu H, Han B, Fan MX, Gu T, Zhao SX, Liu Y, Cheng KX, Song HD, Qiao J. Aromatase deficiency: a novel compound heterozygous mutation identified in a chinese girl with severe phenotype and obvious maternal virilization. Mol Cell Endocrinol 2016;433:66-74.

(15.) Miedlich SU, Karamooz N, Hammes SR. Aromatase deficiency in a male patient - case report and review of the literature. Bone 2016;93:181-186.

(16.) Mazen I, Mcelreavey K, Elaidy A, Kamel AK, Abdel-Hamid MS. Aromatase deficiency due to a homozygous CYP19A1 mutation in a 46,XX egyptian patient with ambiguous genitalia. Sex Dev 2017;11:275-279.

(17.) Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the p450 arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab 1997;82:1739-1745.

(18.) Belgorosky A, Pepe C, Marino R, Guercio G, Saraco N, Vaiani E, Rivarola MA. Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterozygote for two new point mutations of the CYP19 gene. J Clin Endocrinol Metab 2003;88:5127-5131.

(19.) Lin L, Ercan O, Raza J, Burren CP, Creighton SM, Auchus RJ, Dattani MT, Achermann JC. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metab 2007;92:982-990.

(20.) Unal E, Yildirim R, Tas FF, Demir V, Onay H, Haspolat YK. Aromatase deficiency due to a novel mutation in CYP19A1 gene. J Clin Res Pediatr Endocrinol 2018;10:377-381.

(21.) Chen Z, Wang O, Nie M, Elison K, Zhou D, Li M, Jiang Y, Xia W, Meng X, Chen S, Xing X. Aromatase deficiency in a Chinese adult man caused by novel compound heterozygous CYP19A1 mutations: effects of estrogen replacement therapy on the bone, lipid, liver and glucose metabolism. Mol Cell Endocrinol 2015;399:32- 42.

(22.) Lanfranco F Zirilli L, Baldi M, Pignatti E, Corneli G, Ghigo E, Aimaretti G, Carani C, Rochira V A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment. Bone 2008;43:628-635.

(23.) Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocriol Metab 1999;84:4677-4694.

(24.) Kuiri-Hanninen T, Sankilampi U, Dunkel L. Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty Horm Res Paediatr 2014;82:73-80.

(25.) Kuiri-Hanninen T, Kallio S, Seuri R, Tyrvainen E, Liakka A, Tapanainen J, Sankilampi U, Dunkel L. Postnatal development changes in the pituitary-ovarian axis in preterm and term infant girls. J Clin Endocrinol Metab 2011;96:3432-3439.

(26.) Janner M, Fluck CE, Mullis PE. Impact of estrogen replacement throughout childhood on growth, pituitary-gonadal axis and bone in a 46, XX patient with CYP19A1 deficiency. Horm Res Paediatr 2012;78:261-268.

(27.) Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004;89:5898-5907.

[iD] Fatma Dursun (1), [iD] Serdar Ceylaner (2)

(1) Umraniye Training and Research Hospital, Clinic of Pediatric Endocrinology, Istanbul, Turkey

(2) Intergen Genetic Centre, Medical Geneticist, Ankara, Turkey

Address for Correspondence: Fatma Dursun MD, Umraniye Training and Research Hospital, Clinic of Pediatric Endocrinology, Istanbul, Turkey

Phone: +90 505 267 14 03 E-mail: ORCID ID:

Confict of interest: None declared

Received: 24.05.2018

Accepted: 02.08.2018

DOI: 10.4274/jcrpe.galenos.2018.2018.0140
Table 1. Results of classical adrenocorticotropic hormone stimulation
test at ages 60 days and 2 years

                                    Postnatal 60 days
Time of blood sampling (minutes)    0'           30'

Cortisol ([micro]g/dL)                 1.7       12.8
(NL: 0': 6.5/30': 20)
17OHP (ng/mL)                         65         80
(NL: 0':1.2-8.4/60': 40)
Progesterone (ng/mL)                   7.9        9.5
(NL: 0': 0.34/60': 1.0)
Testosterone (ng/mL)                   0.9        2.1
(NL: 0.05-1.6)
androstenodione (ng/mL)                1.5        2.3
(NL: 0.1-0.3)
ACTH (IU/L)                           12          -
(NL: 0-63)
DHEAS ([micro]g/dL)                 1500          -
(NL: 123-882)
Renin (ng/mL/hour)                     5.4        -
(NL: 0.48-4.8)
Aldosterone (pg/mL)                  375          -
(NL: 35-300)

                                  Age 2 years
Time of blood sampling (minutes)   0'       30'      60'

Cortisol ([micro]g/dL)              6.5     20.3     21
(NL: 0': 6.5/30': 20)
17OHP (ng/mL)                       0.28     1.35     1.4
(NL: 0':1.2-8.4/60': 40)
Progesterone (ng/mL)                0.1      0.8      1.0
(NL: 0': 0.34/60': 1.0)
Testosterone (ng/mL)               <0.13    <0.13    <0.13
(NL: 0.05-1.6)
androstenodione (ng/mL)            <0.3      -       <0.3
(NL: 0.1-0.3)
ACTH (IU/L)                        12        -        -
(NL: 0-63)
DHEAS ([micro]g/dL)                 5.5      -        -
(NL: 123-882)
Renin (ng/mL/hour)                  0.8      -        -
(NL: 0.48-4.8)
Aldosterone (pg/mL)               144        -        -
(NL: 35-300)

17OHP: 17-hydroxy progesterone, ACTH: adrenocorticotropic hormone,
DHEAS: dehydroepiandrosteron sulphate, NL: normal level

Table 2. Laboratory findings of the patient at diagnosis and follow-up

                        2 months

LH (IU/L)               0.48
FSH (IU/L)              1.3
Estradiol (pg/mL)       <10
IGF-1 (ng/mL)           -
Bone age (years)        -
Pelvic ultrasonography  Uterus: 20 mm

BMD                     -

                        26 months

LH (IU/L)                2.43
FSH (IU/L)              46.67
Estradiol (pg/mL)       10
IGF-1 (ng/mL)           11.7
Bone age (years)         2
Pelvic ultrasonography  Uterus: 16 mm, right ovary: 0.6 mL,
                        left ovary: 0.5 mL
BMD                     -

                        52 months

LH (IU/L)                 0.61
FSH (IU/L)               32.8
Estradiol (pg/mL)       <10
IGF-1 (ng/mL)           144
Bone age (years)          3
Pelvic ultrasonography  Uterus: 30 mm, right ovary: 0.4 mL,
                        left ovary: could not be detected
BMD                     -1.4 SD

LH: luteinizing hormone, FSH: follicle stimulating hormone, IGF-1:
insulin-like growth factor-1, BMD: bone mineral density, SD: standard
COPYRIGHT 2019 Galenos Yayinevi Tic. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CASE REPORT
Author:Dursun, Fatma; Ceylaner, Serdar
Publication:Journal of Clinical Research in Pediatric Endocrinology
Date:Jun 1, 2019
Previous Article:Effect of Education on Impaired Hypoglycemia Awareness and Glycemic Variability in Children and Adolescents with Type 1 Diabetes Mellitus.
Next Article:Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |